Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 USD | -3.00% | -4.47% | -12.48% |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
04-29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.48% | 20.2M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech : Signs Clinical Trial Agreement to Test Ampligen Against Common Cold, Influenza A Viruses